RPID RAPID MICRO BIOSYSTEMS, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1380106 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.8%
TTM net income YoY-15.1%
TTM EPS YoY-6.0%
Revenue 3-yr CAGR21.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-133.0%
Net margin-138.2%
FCF margin-121.7%
EBITDA margin-125.3%
Returns
ROE-191.8%
ROA-77.2%
ROIC (approx.)-118.5%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets81.5%
Debt / equity2.18x
Current ratio2.20x
Interest coverage-18.93x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.53M | $8.05M | $8.00M | $11.28M | $7.84M | $7.26M | $7.21M | $8.22M |
| Cost of revenue | $7.13M | $6.84M | $7.63M | — | $7.14M | $6.99M | $6.80M | — |
| Gross profit | $2.40M | $1.21M | $371,000 | — | $696,000 | $275,000 | $404,000 | — |
| R&D expense | $2.97M | $3.33M | $3.36M | $3.22M | $3.53M | $3.23M | $3.62M | $3.40M |
| SG&A expense | $6.33M | $6.77M | $7.44M | $5.34M | $5.64M | $6.08M | $5.69M | $4.83M |
| Operating income | -$10.64M | -$12.32M | -$13.85M | -$12.21M | -$11.37M | -$12.15M | -$11.66M | -$10.23M |
| Interest expense | $632,000 | $646,000 | $639,000 | $673,000 | $393,000 | $12,000 | $12,000 | $12,000 |
| Income tax | $21,000 | $45,000 | $8,000 | $14,000 | $8,000 | $11,000 | $7,000 | -$9,000 |
| Net income | -$11.27M | -$12.92M | -$14.28M | -$12.50M | -$11.51M | -$11.86M | -$11.26M | -$9.67M |
| EBITDA | -$9.99M | -$11.65M | -$13.15M | -$11.42M | -$10.57M | -$11.34M | -$10.81M | -$9.36M |
| EPS (basic) | -0.23 | -0.27 | -0.31 | — | -0.26 | -0.27 | -0.26 | — |
| EPS (diluted) | -0.23 | -0.27 | -0.31 | — | -0.26 | -0.27 | -0.26 | — |
| Weighted avg. shares (diluted) | 48.88M | 48.35M | 45.43M | — | 44.96M | 44.65M | 43.99M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.62M | $14.69M | $13.81M | $20.03M | $19.23M | $18.62M | $19.27M | $17.28M |
| Short-term investments | $102,000 | $5.08M | $9.13M | $18.27M | $22.30M | $12.92M | $22.76M | $33.82M |
| Receivables | $7.67M | $5.51M | $6.37M | $3.13M | $5.43M | $6.05M | $4.52M | $7.52M |
| Inventory | $19.66M | $18.92M | $17.45M | $17.59M | $21.07M | $20.56M | $20.72M | $20.20M |
| Current assets | $36.32M | $46.26M | $49.23M | $61.17M | $69.95M | $60.15M | $69.18M | $80.92M |
| PP&E, net | $7.55M | $8.16M | $8.77M | $8.97M | $9.58M | $10.21M | $10.56M | $11.19M |
| Total assets | $47.57M | $58.45M | $62.36M | $74.85M | $84.41M | $75.59M | $85.43M | $98.17M |
| Current liabilities | $16.51M | $18.15M | $19.12M | $18.49M | $16.55M | $16.40M | $15.00M | $17.57M |
| Long-term debt | $19.22M | $19.14M | $19.05M | $18.90M | $18.83M | — | — | $0 |
| Total debt | $19.22M | $19.14M | $19.05M | $18.90M | $18.83M | — | — | $0 |
| Total liabilities | $38.76M | $40.70M | $41.97M | $41.65M | $40.08M | $21.04M | $19.94M | $22.82M |
| Shareholders' equity | $8.81M | $17.75M | $20.40M | $33.21M | $44.33M | $54.55M | $65.49M | $75.35M |
| Net debt | $12.60M | $4.45M | $5.24M | -$1.13M | -$402,000 | — | — | -$17.28M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.56M | -$12.70M | -$15.06M | -$3.25M | -$9.05M | -$9.70M | -$9.06M | -$9.91M |
| Capital expenditure | $50,000 | -$223,000 | $394,000 | $92,000 | $73,000 | $366,000 | $319,000 | $98,000 |
| Free cash flow | -$13.61M | -$12.48M | -$15.45M | -$3.34M | -$9.12M | -$10.07M | -$9.38M | -$10.01M |
| Investing cash flow | $4.86M | $4.22M | $8.60M | $3.89M | -$9.58M | $9.34M | $10.68M | $4.86M |
| Financing cash flow | $625,000 | $9.35M | $247,000 | $443,000 | $19.25M | -$298,000 | $379,000 | -$6,000 |
| Depreciation & amortization | $647,000 | $674,000 | $706,000 | $790,000 | $804,000 | $811,000 | $847,000 | $869,000 |
| Stock-based compensation | $1.33M | $1.32M | $1.22M | $627,000 | $1.15M | $1.22M | $1.04M | $689,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.